Introduction
Glutamate is the principal excitatory neurotransmitter in the brain, exerting its actions through distinct classes of receptors predominantly localized to neuronal synapses. The glutamate-gated ion channel (iGluR) family consists of the kainate, a-amino-3-hydroxy-S-methylisoxazole-4-propionic acid (AMPA), and N-methyl-D-aspartate (NMDA) subfamilies of receptors. All these receptors flux ions that depolarize neuronal plasma membranes; however, they perform very distinct functions at the synapse and in neural processing more generally. KARs have distinguished themselves functionally as unconventional members of the iGluR receptor family. They are distributed throughout the brain but, unlike AMPA receptors (AMPARs) and NMDA receptors (NMDARs), are not predominantly found in excitatory postsynaptic signaling complexes. Instead, KARs act principally as modulators of synaptic transmission and neuronal excitability. More peculiarly, they link to metabotropic signaling pathways in addition to operating as conventional ionotropic receptors. These modulatory roles position KARs as potentially favorable targets for the development of therapeutics, and KAR antagonists have been examined for amelioration of a diverse range of neurological conditions, including chronic pain, epilepsy and migraine [1] .
Elucidation of the biological function of neuronal KARs has taken place during an extraordinarily productive period in neuroscience initiated by the cloning of the first iGluR subunits [2] and the identification of the first KAR subunit gene [3] . In this review we provide a perspective of the research that has followed these achievements over the past two decades (Figure 1 ) and celebrate the coming of age of KARs.
The early years: the emergence of a new glutamate receptor subfamily Pharmacological and toxicological research into the actions of kainic acid (KA), a natural conformational analog of glutamate isolated from seaweed, pre-dated the cloning of its target receptors by well over a decade. KA is a powerful neurotoxin that elicits a complex spectrum of effects when injected into the mammalian brain, including neuropathological lesions and seizures reminiscent of those found in patients with mesial temporal lobe epilepsy (mTLE) [4, 5] .
Early pharmacological evidence supported the hypothesis that excitatory amino acid receptors mediate the neurotoxic effects of KA [6] . Pioneering pharmacological studies led to the differentiation of vertebrate excitatory amino acid receptors into the AMPAR, NMDAR and KAR subfamilies (reviewed in [7] ). The anatomical distribution of high-affinity binding sites for KA corresponded well to brain regions particularly susceptible to injections of moderate amounts of the toxin, such as the CA3 region of the hippocampus [4, 5, 8] . KA also had a potent depolarizing activity on dorsal root fibers in the spinal cord [9] which arise from a subpopulation of dorsal root ganglion neurons predominantly expressing KARs instead of AMPARs or NMDARs [10] .
Cloning and structural characterization of KARs Molecular cloning Cloning the cDNAs encoding KAR subunits clearly established that these subunits constitute a functionally and structurally distinct family of iGluRs. The first KAR subunit cDNA, GluR5, was isolated in 1990 [3], shortly after the cloning of the four AMPAR subunits [11] [12] [13] , and these represented fundamental breakthroughs in
